Having trouble accessing articles? Reset your cache.

MS Society calls out Biogen, Alkermes on Vumerity price

The National Multiple Sclerosis Society is once again standing up to companies for their pricing of new drugs. This time, the group has called out the price of Biogen and Alkermes’ newly launched Vumerity and asked the companies to refrain from excessive price hikes. Biogen said it would work with payers to tie drug costs to patient outcomes.

Biogen Inc. (NASDAQ:BIIB)

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers